Travere Therapeutics (NASDAQ:TVTX) CEO Eric Dube Sells 108,493 Shares of Stock

Travere Therapeutics, Inc. (NASDAQ:TVTX) CEO Eric Dube sold 108,493 shares of the business’s stock in a transaction on Thursday, September 17th. The stock was sold at an average price of $64.61, for a total value of $7,009,732.73. Following the completion of the transaction, the chief executive officer directly owned 432,886 shares of the company’s stock, valued at approximately $27,968,764.46. The trade was a 20.04% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Travere Therapeutics Trading Up 2.0%

Shares of NASDAQ TVTX opened at $64.74 on Friday. Travere Therapeutics, Inc. has a 1-year low of $22.06 and a 1-year high of $68.73. The business has a fifty day moving average price of $61.63 and a 200 day moving average price of $48.50. The stock has a market capitalization of $6.10 billion, a P/E ratio of -140.74 and a beta of 1.05. The company has a debt-to-equity ratio of 24.58, a current ratio of 4.05 and a quick ratio of 3.99.

Travere Therapeutics (NASDAQ:TVTX) last posted its earnings results on Tuesday, August 4th. The company reported ($0.10) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.13) by $0.03. The company had revenue of $169.58 million for the quarter, compared to analyst estimates of $157.27 million. Travere Therapeutics had a negative return on equity of 55.15% and a negative net margin of 7.35%.The firm’s quarterly revenue was up 48.2% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.13 earnings per share. Equities research analysts expect that Travere Therapeutics, Inc. will post -0.54 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on TVTX shares. HC Wainwright boosted their price objective on shares of Travere Therapeutics from $57.00 to $67.00 and gave the stock a “buy” rating in a research note on Tuesday, June 2nd. Citigroup lifted their price target on shares of Travere Therapeutics from $70.00 to $85.00 and gave the stock a “buy” rating in a report on Wednesday, August 5th. TD Cowen upped their price target on Travere Therapeutics from $60.00 to $75.00 and gave the stock a “buy” rating in a research report on Wednesday, August 5th. Weiss Ratings lowered Travere Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, June 23rd. Finally, Guggenheim boosted their target price on Travere Therapeutics from $65.00 to $75.00 and gave the stock a “buy” rating in a research note on Wednesday, August 5th. Ten equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $68.00.

Travere Therapeutics News Roundup

Here are the key news stories impacting Travere Therapeutics this week:

• Positive Sentiment: Brokerages have assigned Travere Therapeutics a consensus rating of “Moderate Buy,” indicating that analysts generally continue to see upside potential in the stock. Travere Therapeutics Given Consensus Rating of Moderate Buy by Brokerages
• Neutral Sentiment: Company management will present at the Stifel 2026 Virtual Immunology and Inflammation Forum on September 24. The event could provide updates on Travere’s rare-disease pipeline and commercial outlook, but no new operating information was announced. Travere Therapeutics to Present at the Stifel 2026 Virtual Immunology and Inflammation Forum
• Negative Sentiment: Multiple insiders, including the CEO, CFO, CAO and EVPs, reduced their holdings, with individual ownership declines ranging from about 7% to 60%. Although the sales were prearranged, concentrated insider selling may raise questions about near-term sentiment and limit the stock’s momentum.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of TVTX. Integrated Wealth Concepts LLC purchased a new position in shares of Travere Therapeutics in the second quarter worth $70,000. JW Asset Management LLC purchased a new stake in shares of Travere Therapeutics during the second quarter valued at $1,704,000. Nykredit A S acquired a new position in shares of Travere Therapeutics in the 2nd quarter valued at $237,000. Allianz Asset Management GmbH acquired a new position in shares of Travere Therapeutics in the 2nd quarter valued at $2,441,000. Finally, Corient Private Wealth LP raised its stake in Travere Therapeutics by 1.4% in the 2nd quarter. Corient Private Wealth LP now owns 48,125 shares of the company’s stock worth $2,734,000 after acquiring an additional 648 shares during the last quarter.

About Travere Therapeutics

Travere Therapeutics, Inc is a biopharmaceutical company focused on developing and commercializing treatments for rare kidney and immune-mediated diseases. The company’s work is centered on conditions with significant unmet medical needs, including diseases that can lead to progressive kidney damage and kidney failure.

Travere’s principal commercial product is FILSPARI (sparsentan), an oral therapy for adults with primary immunoglobulin A nephropathy, or IgA nephropathy, who are at risk of disease progression.